8-K: Omada Health Q2 2025: Revenue Up 49%, Nears Profitability

Omada Health reported strong second quarter 2025 financial results, with revenue increasing 49% year-over-year and significant progress towards profitability.

Summary

• Second quarter 2025 revenue reached $61 million, marking a 49% increase compared to the second quarter of 2024.
• Total members grew by 52% year-over-year, reaching 752,000.
• Net loss significantly improved to $5 million, down from a net loss of $11 million in the second quarter of 2024.
• Adjusted EBITDA loss narrowed substantially to $0.2 million, compared to a loss of $6.8 million in the second quarter of 2024.
• Gross Margin improved to 66% from 60% in the second quarter of 2024, with Non-GAAP Gross Margin at 68% compared to 63%.
• Cash and equivalents stood at $223 million as of June 30, 2025.
• Omada fully repaid its $31.0 million term loan facility and $0.4 million revolving line of credit on July 31, 2025, ahead of their June 1, 2028, contractual maturity.
• The company announced OmadaSpark, a new AI-agent designed to deliver real-time motivational interviewing and nutrition education to members.
• GLP-1 Companion programs showed strong growth and are now available through two of the largest pharmacy benefit managers in the United States.
• For the full year ending December 31, 2025, Omada expects revenue in the range of $235 million to $241 million and an Adjusted EBITDA loss in the range of $9 million to $5 million.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue and member growth, substantial improvements in profitability metrics, and a strengthened balance sheet through early debt repayment. Strategic initiatives like GLP-1 program expansion and AI integration are positive indicators for future growth, despite still operating at a slight loss.

Positives

• Strong revenue growth of 49% year-over-year to $61 million in Q2 2025.
• Significant member growth of 52% year-over-year, reaching 752,000 total members.
• Substantial improvement in profitability metrics: Net Loss reduced from $11 million to $5 million, and Adjusted EBITDA Loss dramatically narrowed from $6.8 million to $0.2 million, nearing breakeven.
• Improved GAAP Gross Margin to 66% from 60% and Non-GAAP Gross Margin to 68% from 63%.
• Successful commercialization and strong growth of GLP-1 Care Track, now accessible via two largest pharmacy benefit managers.
• Innovation with the introduction of OmadaSpark, an AI-agent for enhanced member support.
• Robust cash position with $223 million in cash and equivalents as of June 30, 2025.
• Early repayment of $31.0 million term loan and $0.4 million revolving line of credit, eliminating future interest expense and related debt covenants.

Negatives

• Still operating at a net loss ($5 million) and adjusted EBITDA loss ($0.2 million), though significantly improved.
• Full-year 2025 Adjusted EBITDA guidance still projects a loss in the range of $9 million to $5 million.

Risks

• Limited operating history and ability to manage growth effectively.
• History of net losses and ability to achieve or maintain profitability.
• Ability of programs to achieve and maintain market acceptance.
• Changes in the healthcare industry and competition.
• Growth and success of customers and channel partners.
• Number of individuals covered by programs and the number of programs covered by customers.
• Level of member engagement in programs.
• Ability to maintain and grow customer and channel partner relationships.
• Concentration of a substantial portion of sales among a limited number of customers and channel partners.
• Ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners.
• Ability to increase the size of the organization.
• Dependence on a limited number of third-party suppliers.
• Impact of seasonality on financial results.
• Ability to achieve widespread brand awareness and the impact of any negative media coverage.
• Ability to develop and release new programs and services.
• Cybersecurity threats.
• Dependence on the interoperability of programs and connected devices with third-party devices, operating systems, and applications.
• Changes in laws or regulations or the implementation of existing laws and regulations.
• Compliance with privacy and security laws and regulations.
• Compliance with healthcare regulatory laws.
• Any modification in U.S. Food and Drug Administration enforcement policies.
• Dependence on relationships with affiliated professional entities.

Future Outlook

Omada Health expects full-year 2025 revenue to be in the range of $235 million to $241 million and an Adjusted EBITDA loss in the range of $9 million to $5 million. The company anticipates reduced future interest expense and elimination of related debt covenants due to the recent loan repayment.

Management Comments

• "I'm proud of our second quarter results, with 49% year-over-year revenue growth, strong margin improvements, and continued progress toward profitability."
• "We believe our Q2 performance reflects Omada's ability to capture tailwinds in cardiometabolic care, to effectively commercialize our GLP-1 Care Track, and to leverage advances in artificial intelligence for the benefit of our members."

Industry Context

The results indicate Omada Health is capitalizing on the growing demand for virtual healthcare solutions, particularly in chronic disease management and the emerging GLP-1 companion program market. The integration of AI (OmadaSpark) aligns with broader industry trends towards leveraging technology for personalized and scalable patient engagement. The company's success with Pharmacy Benefit Managers (PBMs) highlights the increasing acceptance and integration of virtual care into mainstream health benefits.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison to global benchmarks. However, the significant year-over-year growth in revenue (49%) and members (52%), coupled with substantial improvements in profitability metrics (net loss and adjusted EBITDA loss reduction), suggest strong performance within the virtual health sector, which often prioritizes growth and market penetration in its early to mid-stages.

Related Party Transactions

• Accounts receivable includes $15.1 million from a related party as of June 30, 2025, compared to $13.2 million as of December 31, 2024.
• Accrued expenses and other current liabilities includes $3.9 million from a related party as of June 30, 2025, compared to $2.2 million as of December 31, 2024.
• Deferred revenue includes $18.7 million from a related party as of June 30, 2025, compared to $13.2 million as of December 31, 2024.
• Services revenue includes $36.5 million from a related party for the three months ended June 30, 2025, compared to $21.2 million for the same period in 2024.
• Hardware revenue includes $2.6 million from a related party for the three months ended June 30, 2025, compared to $1.5 million for the same period in 2024.
• Cost of revenue Services includes $1.2 million from a related party for the three months ended June 30, 2025, compared to $0.8 million for the same period in 2024.
• Research and development expense includes $0.5 million from a related party for the three months ended June 30, 2025, compared to $0.4 million for the same period in 2024.
• Sales and marketing expense includes $6.6 million from a related party for the three months ended June 30, 2025, compared to $3.6 million for the same period in 2024.
• General and administrative expense includes $0.4 million from a related party for the three months ended June 30, 2025, compared to $0.2 million for the same period in 2024.
• Changes in accounts receivable include $1.9 million from related party balances for the six months ended June 30, 2025.
• Changes in accrued expenses and other current liabilities include $1.7 million from related party balances for the six months ended June 30, 2025.
• Changes in deferred revenue include $5.5 million from related party balances for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue and member growth, significant progress towards profitability, improved margins, and a strengthened balance sheet from debt repayment. Strategic initiatives (GLP-1, AI) suggest future growth potential.
• Customers (Health Plans, Health Systems, Employers): Positive impact through expanded program offerings (GLP-1 Care Track), enhanced member engagement tools (OmadaSpark AI), and demonstrated clinical and economic results.
• Members: Positive impact through access to expanded virtual care programs, including GLP-1 companion programs, and enhanced support via new AI-agents like OmadaSpark.
• Creditors: Positive impact from the full and early repayment of outstanding debt, demonstrating strong financial health and liquidity.
• Employees: Positive impact as the company is a certified Great Place to Work and is growing, potentially leading to more opportunities.

Next Steps

• Host a conference call on August 7, 2025, to discuss Q2 results.
• Continue to capture tailwinds in cardiometabolic care.
• Effectively commercialize GLP-1 Care Track.
• Leverage advances in artificial intelligence for member benefit.
• File Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Key Dates

Recommendation

The filing indicates robust operational and financial performance, with significant year-over-year revenue and member growth, coupled with a dramatic reduction in net loss and adjusted EBITDA loss, bringing the company very close to profitability. The strategic advancements in GLP-1 companion programs and AI integration position Omada Health favorably in a high-growth virtual healthcare market. Furthermore, the proactive repayment of all outstanding debt strengthens the balance sheet and eliminates future interest burdens and covenants, signaling strong financial management and liquidity. These factors collectively suggest a strong positive trajectory for the company's stock.

Keywords

Virtual healthcare, digital health, chronic disease management, diabetes, hypertension, prediabetes, musculoskeletal, GLP-1, AI in healthcare, telehealth, health tech, Omada Health, OMDA